The first dual drug HIV therapy approved by the US FDA today

Source: Wuxi Pharmaceutical Co., Ltd on November 22, 2017, the US FDA announced the approval of Juluca, a new drug of Viiv healthcare, for the treatment of specific adult patients infected with HIV-1 It is worth mentioning that this is the first dual drug therapy approved for this indication In contrast, the current standard HIV treatment programs contain no less than 3 drugs HIV is a kind of virus that can weaken the human immune system It can destroy the important immune cells of human body against diseases and infections, and seriously affect the quality of life of patients According to the Centers for Disease Control and Prevention (CDC), there are about 1.1 million people living with HIV in the United States In a specific population, the virus infection is also an important cause of death Juluca, brought by Viiv healthcare, is expected to become a new treatment for HIV infected patients The new drug consists of dolutegravir and rilpivirine Dulutegravir, developed by VIV healthcare, is an integration strand transfer inhibitor (insi) of HIV-1, which can form a combination with other antiretroviral therapies to treat adult patients with HIV-1 infection; rilpivirine, developed by Janssen Sciences Ireland UC, is a non nucleoside reverse transcriptase inhibitor inhibitor，NNRTI）。
In two clinical trials, the safety and effectiveness of Juluca in adults were evaluated In the two studies, 1024 volunteers were recruited, and their viral status has been effectively controlled in the current anti HIV therapy The volunteers were randomly divided into two groups, one group continued to receive current anti HIV therapy, and the other group used Juluca Research has shown that Juluca can effectively inhibit HIV, which is equivalent to the anti HIV therapy used by these volunteers In terms of side effects, Juluca is the most common cause of diarrhea and headaches Serious side effects include rashes and allergic reactions, liver problems, and emotional changes such as depression The FDA's announcement states that Juluca cannot be used in combination with other anti HIV drugs, and may also react with common drugs "Juluca provides dual drug maintenance therapy for patients whose virus has been suppressed This group of patients will benefit from this once-a-day NRTI free protocol As World AIDS Day approaches in 2017, we are aware that this approval can bring about changes in treatment paradigms for HIV infected patients, "said Dr Debra birnkrant, head of antiviral products at the FDA drug evaluation and research center." limiting the number of drugs in HIV therapy can reduce the toxicity to patients " There are 10 days left for World AIDS Day 2017 As this day comes, we thank the researchers for bringing new therapies to this special group of patients, and we hope that this effective new therapy with less drugs can further improve the lives of HIV patients.